Story perspectives

AstraZeneca Shares Drop 9% After Heart-Drug Trial Failure

7/10/2026

Summary

AstraZeneca Trial Failure

AstraZeneca shares fell up to 9% on July 9, 2026 after its Phase III heart-drug trial failed.
The Wainua trial with Ionis showed no reduction in deaths or heart events versus placebo in ATTR-CM patients.
The miss erased about £19 billion (US$24 billion) from AstraZeneca’s market value and cut peak-sales forecasts to roughly US$4 billion, modeling $2.5 billion less revenue.
Alnylam shares rose ~16% and BridgeBio ~15%, while Ionis fell 19% after the news.

Summary

AstraZeneca Misses

AstraZeneca's Wainua trial missed its primary endpoint, drawing scrutiny toward CEO Pascal Soriot, who built the company into a cancer-drug powerhouse.
Wainua is a gene-silencer that blocks abnormal liver protein production, a novel approach to transthyretin-mediated amyloid cardiomyopathy, which AstraZeneca estimates affects up to half a million people worldwide.
The study hinted at benefit in a predefined subgroup not receiving stabilizer therapy, indicating the need for additional trials.

Summary

AstraZeneca Delay

AstraZeneca’s failure to meet the primary endpoint will likely delay generic gene-silencing therapies in African markets.
AstraZeneca reported a comparable safety profile for Wainua with no new adverse signals, planning to present the data at European Society of Cardiology Congress in August 2026.
The CARDIO-TTRansform trial enrolled 1,432 patients at 130 sites in 20 countries, largest late-stage ATTR-CM study, with 57 percent on a transthyretin stabilizer—a subgroup where Wainua showed no effect.

History

Historical Context

In August 2018 Alnylam secured FDA approval for patisiran, the first siRNA drug for hereditary ATTR polyneuropathy; by 2020 it served 1,050 patients and generated $65.5 million. After eplontersen (Wainua) received U.S. approval in December 2023, AstraZeneca’s July 9 2026 trial failure revived the risk-averse pharma global climate that followed the 2018 launch.

1 of 4

AstraZeneca Trial Failure

AstraZeneca shares fell up to 9% on July 9, 2026 after its Phase III heart-drug trial failed.
The Wainua trial with Ionis showed no reduction in deaths or heart events versus placebo in ATTR-CM patients.
The miss erased about £19 billion (US$24 billion) from AstraZeneca’s market value and cut peak-sales forecasts to roughly US$4 billion, modeling $2.5 billion less revenue.
Alnylam shares rose ~16% and BridgeBio ~15%, while Ionis fell 19% after the news.

1 / 4